服用奥拉迪约需要注意什么事项？

Oradejo is the first targeted oral therapy approved to prevent HAE attacks. The approval of this drug will bring significant progress in the treatment of HAE patients and help reduce the treatment burden on patients. It is a plasma kallikrein inhibitor that binds to plasma kallikrein and inhibits its proteolytic activity. Today let’s take a closer look at what you need to pay attention to when taking Oradejo?

1. Risk of QT prolongation at higher than recommended doses: Oradejo should not be used to treat acute attacks of HAE. Additional once daily doses or doses higher than 150 mg of Oradejo are not recommended. A concentration-dependent increase in QT was observed at doses above the recommended daily dose of 150 mg.

2. Drug interactions: Inform patients that Oladijo may interact with other drugs. Advise patients to report the use of any other prescription or over-the-counter medications or herbal products to their physician.

3. Not suitable for the acute treatment of acute ischemic encephalopathy: It is recommended that patients take commonly used rescue drugs to treat acute ischemic encephalopathy. Inform patients that the safety and effectiveness of using Oladijo as an acute treatment for HAE attacks have not been established. Advise patients not to take daily doses of more than 150 mg or additional doses of Oradejo once daily to treat acute exacerbations of HAE due to the risk of QT prolongation.

4. Oradejo recommended dosage: Take one capsule (150mg) orally once a day with food. Patients should not increase or decrease the drug dosage without authorization while receiving Oladiyo treatment. Increasing the drug dosage will not make the condition improve quickly, but will lead to adverse reactions. Therefore, patients should strictly follow the doctor's diagnosis and treatment recommendations and should not use medication without authorization. Patients who are allergic to any of the ingredients in Oradejo should not use this product for treatment.

Oradejo was safe and well-tolerated in both studies, with the most common adverse reaction compared with placebo being gastrointestinal. Usually the incidence is higher in the early stages of treatment, then gradually decreases, and patients usually resolve on their own.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.